FibroGen, Inc (FGEN) News
Filter FGEN News Items
FGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest FGEN News From Around the Web
Below are the latest news stories about FIBROGEN INC that investors may wish to consider to help them evaluate FGEN as an investment opportunity.
FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call TranscriptFibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript November 6, 2023 FibroGen, Inc. beats earnings expectations. Reported EPS is $-0.52, expectations were $-0.68. Operator: Hello and welcome to the FibroGen’s Third Quarter 2023 Earnings Call. At this time, all participants are in listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator […] |
Q3 2023 FibroGen Inc Earnings CallQ3 2023 FibroGen Inc Earnings Call |
FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net RevenueStrong Roxadustat Volume Growth in China and Successful Cost Reduction Plan Boosts Performance |
FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesThe headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
FibroGen Reports Third Quarter 2023 Financial ResultsTopline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer Third quarter net revenue of $40.1 million, an increase of 155% year over year Roxadustat sNDA accepted in China for chemotherapy-induced anemia Robust roxadustat volume growth of 37% in ChinaStrong execution of cost reduction plan reaffirming cash runway into 2026 SAN FRANCI |
FibroGen to Report Third Quarter 2023 Financial ResultsSAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the “Investor Relations” pag |
7 Stocks to Sell Before the Axe FallsWhile an uncomfortable topic to discuss, consistent success in the market will require an objective view of stocks to sell. |
Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & MoreRegulatory updates from Fibrogen (FGEN) and Bristol Myers (BMY) are in focus in the biotech sector. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday morning and we're covering the shares rising and falling this morning! |
FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23%FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to meet the primary endpoint. |